Allegro Ophthalmics to begin two phase 2 studies of integrin peptide therapy

The U.S. Food and Drug Administration approved an investigational new device application from Allegro Ophthalmics to begin two phase 2 studies of an integrin peptide therapy for patients with wet age-related macular degeneration or symptomatic vitreomacular traction, according to a news release. These will be the fifth and sixth studies of ALG-1001 integrin peptide therapy.

Full Story →